This product review focusses on the use of olopatadine hydrochloride and mometasone furoate monohydrate nasal spray in the treatment of allergic rhinitis. This review discusses the evidence in support of the use of this nasal spray, its dosage, interactions, safety, and efficacy and tolerability demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Connie Katelaris, Head of Unit, Immunology & Allergy, Campbelltown Hospital, Campbelltown, NSW, and Professor Richard Harvey, a dedicated rhinologist at Macquarie University and St Vincent’s Hospitals in Sydney.
Please login below to download this issue (PDF)